Knowledge about the success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR-T therapy without a conditioning regimen is limited.<h4>Case presentation</h4>We report a patient with relapsed/refractory (R/R) Ph<sup>+</sup> B-cell acute lymphoblastic leukemia (ALL) who underwent anti-CD19 CAR-T immunotherapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.